In Brief: Advertising Regulation, Vansen Consumer, Star Scientific

Supplement firms’ claims referred to FDA, FTC; review prompts new script for Zvelt ads; Vansen starts consumer portfolio with Canadian deal; Star Scientific pivots to drug development; and more In Brief.

Council of Better Business Bureaus industry self-regulation arms referred to the Federal Trade Commission advertising by nutritional product marketers Elements of Health Care LLC and Natures Flava LLC after the firms failed to provide support for product claims. The Electronic Retailing Self-Regulation Program on March 18 said it also referred direct-response advertising for Sanford, Fla.-based Natures Flava’s Dinamo supplement, which made claims, including customer testimonials, for treating diabetes. The National Advertising Division on March 14 referred to FTC ad claims for Lindon, Utah-based Elements of Health Care’s L’Arginine Plus supplements, including “Sharper and improved memory, restful sleeping and morning alertness, increased metabolism, reduction in menopause and PMT symptoms and a whole range of other benefits have all been linked to L-arginine.” CBBB’s divisions refer cases to FTC and FDA when firms refuse to provide substantiating evidence for claims or fail to follow recommendations following reviews.

Progenum International LLC is changing advertising for its Zvelt “fat loss patch” based on the Electronic Retailing Self-Regulation Program’s review....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United Kingdom

BioMarin Fights Back After NICE Blocks English Funding For £500K Batten Disease Drug

 

The health technology assessment institute, NICE, said the price BioMarin was asking for Brineura was too high, even though its appraisal committee applied a cost-effectiveness threshold ten times higher than usual.

UK Initiative Steps Up Efforts To Tackle Recruitment Bottlenecks In Dementia Trials

 

A government-backed program is working on improving the ability to run dementia clinical trials in the UK, and access to trials for participants.

Why Chiesi’s Raxone Faced A Decade-Long Wait For English Funding

 

Chiesi’s orphan drug Raxone has secured an English funding recommendation for the treatment of Leber's hereditary optic neuropathy, a decade after the orphan drug was approved for marketing. Chiesi told the Pink Sheet about its “long, and often challenging” road to reimbursement.

New Advisory Group To Shape UK’s Simplified Informed Consent Process

 

Although the UK Health Research Authority’s initial proposal for simplified informed consent was rejected by stakeholders, it has yielded valuable insights into reducing trial burden and widening access

More from Europe

UK Initiative Steps Up Efforts To Tackle Recruitment Bottlenecks In Dementia Trials

 

A government-backed program is working on improving the ability to run dementia clinical trials in the UK, and access to trials for participants.

Danish Probe Could Influence Rethink Of Controversial EU Urban Wastewater Rules

 

Some medicines may be subject to price rises that make them unaffordable if the burden of paying for extra wastewater treatment is not more fairly distributed across different industries, the Danish pharmaceutical industry association has warned.

EMA Revives Face-To-Face Oral Explanations In Response To Industry Feedback

 
• By 

The European Medicines Agency is bringing back in-person oral explanation meetings with drug sponsors on a pilot basis, following industry feedback that direct engagement with its scientific committees is highly valued.